Anti-cytotoxic T-lymphocyte antigen-4 antibody: The first in an emerging class of immunomodulatory antibodies for cancer treatment

Journal of Clinical Oncology

Volumn 26, Issue 32, 2008, Pages 5275-5283

  Fong, Lawrence ^a   Small, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD137 ANTIGEN; CD40 ANTIGEN; CYTOTOXIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; DEXAMETHASONE; DOCETAXEL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN; MELANOMA VACCINE; MONOCLONAL ANTIBODY; PACLITAXEL; SUNITINIB; TEMOZOLOMIDE; TICILIMUMAB; TRIACYLGLYCEROL LIPASE;

ADRENAL INSUFFICIENCY; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; COLITIS; COLON CANCER; COMBINATION CHEMOTHERAPY; DERMATITIS; DIARRHEA; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ENTEROCOLITIS; FATIGUE; HEADACHE; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNE SYSTEM; IMMUNOMODULATION; IMPOTENCE; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA; MELENA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; NAUSEA; OVARY CANCER; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UVEITIS; VISUAL FIELD DEFECT; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; TREATMENT OUTCOME;

EID: 55949083407     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.8954     Document Type: Article

References (83)

1. Weng WK, Levy R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 21:3940-3947, 2003
2. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc-gammaRIIIa gene. Blood 99:754-758, 2002
3. Hatjiharissi E, Xu L, Santos DD, et al: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 110:2561-2564, 2007
4. Zhang W, Gordon M, Schultheis AM, et al: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712-3718, 2007
5. Greenberg PD, Klarnet JP, Kern DE, et al: Therapy of disseminated tumors by adoptive transfer of specifically immune T cells. Prog Exp Tumor Res 32:104-127, 1988
6. Muranski P, Boni A, Wrzesinski C, et al: Increased intensity lymphodepletion and adoptive immunotherapy: How far can we go? Nat Clin Pract Oncol 3:668-681, 2006
7. Rosenberg SA, Yang JC, Restifo N: Cancer immunotherapy: Moving beyond current vaccines. Nat Med 10:909-915, 2004
8. Jäger D: Potential target antigens for immunotherapy identified by serological expression cloning (SEREX). Methods Mol Biol 360:319-326, 2007
9. Gunawardana CG, Diamandis EP: High throughput proteomic strategies for identifying tumour-associated antigens. Cancer Lett 249:110-119, 2007
10. Hudson ME, Pozdnyakova I, Haines K, et al: Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 104:17494-17499, 2007
11. Wang X, Yu J, Sreekumar A, et al: Autoantibody signatures in prostate cancer. N Engl J Med 353:1224-1235, 2005
12. Haanen JB, Baars A, Gomez R, et al: Melanoma-specific tumor-infiltrating lymphocytes but not circulating melanoma-specific T cells may predict survival in resected advanced-stage melanoma patients. Cancer Immunol Immunother 55: 451-458, 2006
13. de Vries IJ, Bernsen MR, Lesterhuis WJ, et al: Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23:5779-5787, 2005
14. Shevach EM, McHugh RS, Piccirillo CA, et al: Control of T-cell activation by CD4+ CD25+ suppressor T cells. Immunol Rev 182:58-67, 2001
15. Ghiringhelli F, Menard C, Terme M, et al: CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 202:1075-1085, 2005
16. Diaz-Montero CM, Salem ML, Nishimura MI, et al: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother [epub ahead of print on April 30, 2008]
17. Blank C, Gajewski TF, Mackensen A: Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: Implications for tumor immunotherapy. Cancer Immunol Immunother 54:307-314, 2005
18. Stowell SR, Qian Y, Karmakar S, et al: Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J Immunol 180:3091-3102, 2008
19. Zamanakou M, Germenis AE, Karanikas V: Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 111:69-75, 2007
20. Oppenheim DE, Roberts SJ, Clarke SL, et al: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6:928-937, 2005
21. Nagaraj S, Gabrilovich DI: Myeloid-derived suppressor cells. Adv Exp Med Biol 601:213-223, 2007
22. Korman AJ, Peggs KS, Allison JP: Checkpoint blockade in cancer immunotherapy. Adv Immunol 90:297-339, 2006
23. Krummel MF, Allison JP: CD28 and CTLA4 have opposing effects on the response of T cells to stimulation. J Exp Med 182:459-465, 1995
24. Krummel MF, Sullivan TJ, Allison JP: Superantigen responses and co-stimulation: CD28 and CTLA4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol 8:519-523, 1996
25. Krummel MF, Allison JP: CTLA4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 183:2533-2540, 1996
26. Chambers CA, Krummel MF, Boitel B, et al: The role of CTLA4 in the regulation and initiation of T-cell responses. Immunol Rev 153:27-46, 1996
27. Linsley PS, Greene JL, Brady W, et al: Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA4 receptors. Immunity 1:793-801, 1994
28. Korman A, Yellin M, Keler T: Tumor immunotherapy: Preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Investig Drugs 6:582-591, 2005
29. Tivol EA, Borriello F, Schweitzer AN, et al: Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA4. Immunity 3:541-547, 1995
30. Waterhouse P, Penninger JM, Timms E, et al: Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 270:985-988, 1995
31. Peggs KS, Quezada SA, Korman AJ, et al: Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18:206-213, 2006
32. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA 4 blockade. Science 271:1734-1736, 1996
33. Kwon ED, Hurwitz AA, Foster BA, et al: Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci U S A 94:8099-8103, 1997
34. Sotomayor EM, Borrello I, Tubb E, et al: In vivo blockade of CTLA4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance. Proc Natl Acad Sci U S A 96:11476-11481, 1999
35. Shrikant P, Khoruts A, Mescher MF: CTLA4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. Immunity 11:483-493, 1999
36. Hurwitz AA, Yu TF, Leach DR, et al: CTLA4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc Natl Acad Sci U S A 95:10067-10071, 1998
37. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anticytotoxic T lymphocyte-associated antigen 4 (CTLA4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366, 1999
38. Hurwitz AA, Foster BA, Kwon ED, et al: Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA4 blockade. Cancer Res 60:2444-2448, 2000
39. Mokyr MB, Kalinichenko T, Gorelik L, et al: Realization of the therapeutic potential of CTLA4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res 58:5301-5304, 1998
40. Sutmuller RP, van Duivenvoorde LM, van Elsas, et al: Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823-832, 2001
41. Davila E, Kennedy R, Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA4 blockade. Cancer Res 63:3281-3288, 2003
42. Demaria S, Kawashima N, Yang AM, et al: Immune-mediated inhibition of metastases after treatment with local radiation and CTLA4 blockade in a mouse model of breast cancer. Clin Cancer Res 11:728-734, 2005
43. Lenz H: Management and preparedness for infusion and hypersensitivity reactions. Oncologist 12:601-609, 2007
44. Maker AV, Attia P, Rosenberg SA: Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA4 blockade. J Immunol 175:7746-7754, 2005
45. Kavanagh B, O'Brien S, Lee D, et al: CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112:1175-1183, 2008
46. Reference deleted
47. Maker AV, Yang JC, Sherry RM, et al: Intrapatient dose escalation of anti-CTLA4 antibody in patients with metastatic melanoma. J Immunother 29:455-463, 2006
48. Chambers CA, Sullivan TJ, Truong T, et al: Secondary but not primary T cell responses are enhanced in CTLA4-deficient CD8+ T cells. Eur J Immunol 28:3137-3143, 1998
49. Jinushi M, Hodi FS, Dranoff G: Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A 103:9190-9195, 2006
50. Contardi E, Palmisano GL, Tazzari PL, et al: CTLA4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 117:538-550, 2005
51. Small EJ, Tchekmedyian NS, Rini BI, et al: A pilot trial of CTLA4 blockade with human anti-CTLA4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 13:1810-1815, 2007
52. Tchekmedyian S, Glasby J, A Korman A, et al: MDX-010 (human anti-CTLA4): A phase I trial in malignant melanoma. Proc Am Soc Clin Oncol 21:15a, 2002 (abstr 56)
53. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717, 2003
54. Weber JS, Hersh EM, Yellin MJ, et al: The efficacy and safety of ipilimumab (MDX-010) in subjects with unresectable stage III or stage IV malignant melanoma. J Clin Oncol 25:477s, 2007 (suppl; abstr 8523)
55. Hamid O: Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study. J Clin Oncol 26:489s, 2008 (suppl; abstr 9025)
56. O'Day SJ: Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies. J Clin Oncol 26:488s, 2008 (suppl; abstr 9021)
57. Weber J: Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma. J Clin Oncol 26:485s, 2008 (suppl; abstr 9010)
58. Peggs KS, Segal NH, Allison JP: Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative. Cancer Cell 12:192-199, 2007
59. Hersh EM, Weber JS, Powderley J, et al: Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazine. J Clin Oncol, 26:488s, 2008 (suppl; abstr 9022)
60. Small EJ, Higano C, Tchekmedyian N, et al: Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer. J Clin Oncol 24:243s, 2006 (suppl; abstr 4609)
61. Maker AV, Phan GQ, Attia P, et al: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 12:1005-1016, 2005
62. Attia P, Phan GQ, Maker AV, et al: Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J Clin Oncol 23: 6043-6053, 2005
63. Ribas A, Camacho LH, Lopez-Berestein G, et al: Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23:8968-8977, 2005
64. Ribas A, Bozon A, Lopez-Berestein G, et al: Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma. J Clin Oncol 23:716s, 2005 (suppl; abstr 7524)
65. Ribas A, Antonia S, Sosman J, et al: Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody in patients with advanced melanoma. J Clin Oncol 25:118s, 2007 (suppl; abstr 3000)
66. Ribas A, Hauschild A, Kefford R, et al: Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26:485s, 2008 (suppl; abstr LBA9011)
67. Hamid O, Urba WJ, Yellin MJ, et al: Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma. Eur J Cancer 43:396, 2007 (suppl 5; abstr 7005)
68. Gomez-Navarro J, Antonia S, Sosman J, et al: Survival of patients with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675-206 in a phase I/II study. J Clin Oncol 25:478s, 2007 (suppl; abstr 8524)
69. Hodi SF: Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA4 monoclonal antibody. J Clin Oncol 26:134s, 2008 (suppl; abstr 3008)
70. Antonia S, Sosman J, Kirkwood JM, et al: Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody. J Clin Oncol 25:127s, 2007 (suppl; abstr 3038)
71. Blansfield JA, Beck KE, Tran K, et al: Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother 28:593-598, 2005
72. Beck KE, Blansfield JA, Tran KQ, et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 24:2283-2289, 2006
73. Chen B, Phillips J, Greenbaum M, et al: Efficacy of anti-CTLA4 antibody in the Sa1N tumor model when combined with dexamethasone. Proc Am Assoc Cancer Res 2007 (abstr 2202)
74. Weber J: Review: Anti-CTLA4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events. Oncologist 12:864-872, 2007
75. ClinicalTrials.gov: National Library of Medicine, National Institutes of Health. Available at: Http://www.clinicaltrials.gov
76. Gerritsen W, van den Eertwegh AJ, De Gruijl T, et al: Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mCRPC). J Clin Oncol 25:264s, 2007 (suppl; abstr 5120)
77. Weber JS, Targan S, Scotland R, et al: Phase II trial of extended dose anti-CTLA4 antibody ipilimuimab (formerly MDX-010) with a multi-peptide vaccine for resected stages III and IV melanoma. J Clin Oncol 24:102s, 2006 (suppl; abstr 2510)
78. Hodi SF, Butlera M, Oblec DA, et al: Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 105:3005-3010, 2008
79. Sanderson K, Scotland R, Lee P, et al: Autoimmunity in a phase I trial of a fully human anticytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23:741-750, 2005
80. Sznol M, Hodi FS, Margolin K, et al: Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J Clin Oncol 26:133s, 2008 (suppl; abstr 3007)
81. Dong J, Strome SE, Salo ao DR, et al: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 8:793-800, 2002
82. Brahmer JR, Topalian S, Wollner I, el al: Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol 26: 133s, 2008 (suppl; abstr 3006)
83. Valzasina B, Guiducci C, Dislich H, et al: Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: A novel regulatory role for OX40 and its comparison with GITR. Blood 105:2845-2851, 2005